HOME
SEARCH
RSS FEED
SUBSCRIBE
Use of Vitronectin as a Biomarker for the Detection of Dengue Hemorrhagic Fever
Case ID:
TAB-2601
Web Published:
12/6/2022
Description:
Dengue hemorrhagic fever (DHF) is a severe, potentially deadly infection spread by mosquitos. CDC scientists have identified vitronectin as an important biomarker of DHF. They have shown vitronectin is significantly reduced in DHF and severe dengue infections when compared to dengue non-hemorrhagic fever patients. Presently, DHF is established by assessing antibody concentrations and other rule-of-thumb criteria, but often these assays can be difficult to interpret and lead to false conclusions. Establishing vitronectin levels provides a specific, novel biomarker for DHF, leading to increased accuracy in clinical diagnoses and improved patient outcomes.
Patent Information:
Title
App Type
Country
Serial No.
Patent No.
File Date
Issued Date
Expire Date
Patent Status
Direct Link:
https://nih.technologypublisher.com/tech/Use_of_Vitronectin_as_a_Biomarker_fo r_the_Detection_of_Dengue_Hemorrhagic_Fever
Category(s):
Licensing
Rare / Neglected Diseases
Diagnostics
Infectious Disease
Bookmark this page
Download as PDF
For Information, Contact:
Jeremiah Mitzelfelt
NIH Technology Transfer
301-443-8518
jeremiah.mitzelfelt@nih.gov
Inventors:
Momar Ndao
Kay Tomashek
Betty Poole-Smith
Elizabeth Hunsperger
Keywords:
assay
Biomarker
DA4BXX
DA4XXX
DAXXXX
DENGUE
Detection
diagnostic
DIFFERENTIATION
DXXXXX
FEVER
HEMORRHAGIC
HOST
UB1XXX
Home
|
Search
|
RSS
|
Subscribe
© 2024. All Rights Reserved. Powered by
Inteum